ConductScience.org, home

Paper36057729

Delivery and assessment of a CRISPR/nCas9-based genome editing system on in vitro models of mucopolysaccharidoses IVA assisted by magnetite-based nanoparticles.

Leal AF and 9 others. Sci Rep, 2022. Cited by 26 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Delivery and assessment of a CRISPR/nCas9-based genome editing system on in vitro models of mucopolysaccharidoses IVA assisted by magnetite-based nanoparticles. Papers, record 36057729. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36057729

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Delivery and assessment of a CRISPR/nCas9-based genome editing system on in vitro models of mucopolysaccharidoses IVA assisted by magnetite-based nanoparticles.
PubMed
Journal
Sci Rep
PubMed
Year
2022
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
26
iCite
Relative citation ratio, by iCite
2.17
iCite
Revised in PubMed
2025-07-28
PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Source PubMed

Download CSV of authors

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
ChondroitinsulfatasesMajor topic
MucopolysaccharidosesMajor topic
Mucopolysaccharidosis IVMajor topic
NanoparticlesMajor topic
Clustered Regularly Interspaced Short Palindromic Repeats
Ferrosoferric Oxide
Gene Editing
Glycosaminoglycans
Humans

Source PubMed

Download CSV of topics

References74

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
133636292Evaluation of HIV-1 derived lentiviral vectors as transductors of Mucopolysaccharidosis type IV a fibroblasts.Gene2021https://conductscience.org/library/papers/33636292PubMed
232529345Lysosomal storage diseases: current therapies and future alternatives.J Mol Med (Berl)2020https://conductscience.org/library/papers/32529345PubMed
329122734Gene editing of MPS I human fibroblasts by co-delivery of a CRISPR/Cas9 plasmid and a donor oligonucleotide using nanoemulsions as nonviral carriers.Eur J Pharm Biopharm2018https://conductscience.org/library/papers/29122734PubMed
433379360Characterization of New Proteomic Biomarker Candidates in Mucopolysaccharidosis Type IVA.Int J Mol Sci2020https://conductscience.org/library/papers/33379360PubMed
528375731CRISPR-Cas9 Structures and Mechanisms.Annu Rev Biophys2017https://conductscience.org/library/papers/28375731PubMed
626515130CCN1/CYR61 overexpression in hepatic stellate cells induces ER stress-related apoptosis.Cell Signal2016https://conductscience.org/library/papers/26515130PubMed
722940367The structure of human GALNS reveals the molecular basis for mucopolysaccharidosis IV A.J Mol Biol2012https://conductscience.org/library/papers/22940367PubMed
833111489Human recombinant lysosomal β-Hexosaminidases produced in Pichia pastoris efficiently reduced lipid accumulation in Tay-Sachs fibroblasts.Am J Med Genet C Semin Med Genet2020https://conductscience.org/library/papers/33111489PubMed
935581402Efficient CRISPR/Cas9 nickase-mediated genome editing in an in vitro model of mucopolysaccharidosis IVA.Gene Ther2023https://conductscience.org/library/papers/35581402PubMed
1033578874Epidemiology of Mucopolysaccharidoses Update.Diagnostics (Basel)2021https://conductscience.org/library/papers/33578874PubMed
1130560399Improved Delivery of CRISPR/Cas9 System Using Magnetic Nanoparticles into Porcine Fibroblast.Mol Biotechnol2019https://conductscience.org/library/papers/30560399PubMed
1224726177Molecular testing of 163 patients with Morquio A (Mucopolysaccharidosis IVA) identifies 39 novel GALNS mutations.Mol Genet Metab2014https://conductscience.org/library/papers/24726177PubMed
1332560390PH-Responsive, Cell-Penetrating, Core/Shell Magnetite/Silver Nanoparticles for the Delivery of Plasmids: Preparation, Characterization, and Preliminary In Vitro Evaluation.Pharmaceutics2020https://conductscience.org/library/papers/32560390PubMed
1430323349Tailoring the AAV2 capsid vector for bone-targeting.Pediatr Res2018https://conductscience.org/library/papers/30323349PubMed
1533277608Engineering precision nanoparticles for drug delivery.Nat Rev Drug Discov2021https://conductscience.org/library/papers/33277608PubMed
1630081189CRISPR-Cas9-mediated gene editing in human MPS I fibroblasts.Gene2018https://conductscience.org/library/papers/30081189PubMed
1731641141Evaluation of novel cationic gene based liposomes with cyclodextrin prepared by thin film hydration and microfluidic systems.Sci Rep2019https://conductscience.org/library/papers/31641141PubMed
1816843502Sulforaphane increases the efficacy of doxorubicin in mouse fibroblasts characterized by p53 mutations.Mutat Res2006https://conductscience.org/library/papers/16843502PubMed
1934504088Treatment of skeletal and non-skeletal alterations of Mucopolysaccharidosis type IVA by AAV-mediated gene therapy.Nat Commun2021https://conductscience.org/library/papers/34504088PubMed
2023227124Ultrasound-mediated gene delivery with cationic versus neutral microbubbles: effect of DNA and microbubble dose on in vivo transfection efficiency.Theranostics2012https://conductscience.org/library/papers/23227124PubMed

See all 74 referencesDownload CSV of references

Cited by21

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 26 citations.

PMIDTitleJournalYearIn PapersSource
42782417Characterization of Cellular Alterations in a Novel NAGLU Enzyme-Deficient Cellular Model Generated from U-87MG Cell Line.Neurochem Res2026https://conductscience.org/library/papers/42782417PubMed
42511849Modeling Tay-Sachs Disease in Astrocyte-like Cells Reveals Significant Changes in the Transcriptomic Profile.Int J Mol Sci2026https://conductscience.org/library/papers/42511849PubMed
42510912Advances in Therapies for Mucopolysaccharidoses.Curr Issues Mol Biol2026https://conductscience.org/library/papers/42510912PubMed
42449999A Comprehensive Update on Pompe Disease: From Existing Therapies to Emerging Curative Strategies.Int J Mol Sci2026https://conductscience.org/library/papers/42449999PubMed
41296404Long-Term Liver-Targeted AAV8 Gene Therapy for Mucopolysaccharidosis IVA.Curr Issues Mol Biol2025https://conductscience.org/library/papers/41296404PubMed
41088244Recent advances in mucopolysaccharidosis IVA treatment.Orphanet J Rare Dis2025https://conductscience.org/library/papers/41088244PubMed
41034280Three-dimensional human mucopolysaccharidosis IVA chondrocyte culture reveals significant impairments in the lysosomal-mitochondrial crosstalk.Sci Rep2025https://conductscience.org/library/papers/41034280PubMed
40830872Innovative approaches to combat antibiotic resistance: integrating CRISPR/Cas9 and nanoparticles against biofilm-driven infections.BMC Med2025https://conductscience.org/library/papers/40830872PubMed
40801580CRISPR/Cas-Based Ex Vivo Gene Therapy and Lysosomal Storage Disorders: A Perspective Beyond Cas9.Cells2025https://conductscience.org/library/papers/40801580PubMed
40710901Advances in Diagnosis, Pathological Mechanisms, Clinical Impact, and Future Therapeutic Perspectives in Tay-Sachs Disease.Neurol Int2025https://conductscience.org/library/papers/40710901PubMed
40677837In vivo direct lentiviral gene therapy improves disease pathology in a mucopolysaccharidosis IVA murine model.Mol Ther Methods Clin Dev2025https://conductscience.org/library/papers/40677837PubMed
40430919Evaluation of the PP6D5 Polymer as a Novel Non-Viral Vector in the Development of a CRISPR/nCas9-Based Gene Therapy for Tay-Sachs Disease.Pharmaceutics2025https://conductscience.org/library/papers/40430919PubMed
40362571CRISPR/nCas9-Edited CD34+ Cells Rescue Mucopolysaccharidosis IVA Fibroblasts Phenotype.Int J Mol Sci2025https://conductscience.org/library/papers/40362571PubMed
39446675Lentiviral Vector-Mediated Ex Vivo Hematopoietic Stem Cell Gene Therapy for Mucopolysaccharidosis IVA Murine Model.Hum Gene Ther2024https://conductscience.org/library/papers/39446675PubMed
39044769CRISPR/Cas9 technology in the modeling of and treatment of mucopolysaccharidosis.Biochem Biophys Rep2024https://conductscience.org/library/papers/39044769PubMed
38368436Evidence of epigenetic landscape shifts in mucopolysaccharidosis IIIB and IVA.Sci Rep2024https://conductscience.org/library/papers/38368436PubMed
38107675Iron oxide-coupled CRISPR-nCas9-based genome editing assessment in mucopolysaccharidosis IVA mice.Mol Ther Methods Clin Dev2023https://conductscience.org/library/papers/38107675PubMed
38003337Mucopolysaccharidosis IVA: Current Disease Models and Drawbacks.Int J Mol Sci2023https://conductscience.org/library/papers/38003337PubMed
37762535Evolution of CRISPR/Cas Systems for Precise Genome Editing.Int J Mol Sci2023https://conductscience.org/library/papers/37762535PubMed
36525790The landscape of CRISPR/Cas9 for inborn errors of metabolism.Mol Genet Metab2023https://conductscience.org/library/papers/36525790PubMed

See all 21 cited byDownload CSV of cited by

Genes6

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
AAVS117PubTator's text mininghttps://conductscience.org/library/genes/17NCBI Gene
ANXA5308PubTator's text mininghttps://conductscience.org/library/genes/308NCBI Gene
GALNS2588PubTator's text mininghttps://conductscience.org/library/genes/2588NCBI Gene
GLB12720PubTator's text mininghttps://conductscience.org/library/genes/2720NCBI Gene
IKZF322806PubTator's text mininghttps://conductscience.org/library/genes/22806NCBI Gene
SUMF1285362PubTator's text mininghttps://conductscience.org/library/genes/285362NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36057729

GET https://conductscience.org/api/papers/v1/36057729/references?page=2